Nazartinib

DB16250InvestigationalSmall molecule

Nazartinib is under investigation in clinical trial NCT03529084 (Phase III Study of Nazartinib (EGF816) Versus Erlotinib/gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations).

Mechanism: Pharmacologically active on Epidermal growth factor receptor
Curator reviewed
Formula / weight: C₂₆H₃₁ClN₆O₂ · 495.02 g/mol (avg)
Code names: EGF-816 · NVP-EGF816-NX

Resolves to

Compound

UNIIKE7K32EME8CAS1508250-71-2ChEMBLCHEMBL3787344

Structure

InChIKeyIOMMMLWIABWRKL-WUTDNEBXSA-NSMILESCN(C)C\C=C\C(=O)N1CCCC[C@H](C1)N1C(NC(=O)C2=CC=NC(C)=C2)=NC2=C1C(Cl)=CC=C2

Targets

P00533EGFR

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

39Drug interactionsStructured to mechanism, not free text

10Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Nazartinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account